A new study is the first using multigene panel testing to examine potentially important mutations among patients with early-onset colorectal cancer. Here’s how it suggests screening should change.
Several surgeons, physicians and specialists helped design Cleveland Clinic’s new cancer building, creating an environment for efficient treatment and care for patients.
By following multiple generations of families affected by hereditary colorectal cancer syndromes, Cleveland Clinic’s Jagelman Registries are preventing cancer mortality in the third generation.
In order to make better treatment decisions for patients with rectal cancer, Cleveland Clinic researchers are exploring use of tumor gene signatures to more accurately determine lymph node status before surgery.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic researchers find a significant number of colorectal cancer patients over age 70 have Lynch syndrome. Study supports universal tumor screening across all age groups to prevent cancers in future generations.
Cleveland Clinic research uncovers the influence of cancer-associated fibroblasts and secretion of the cytokine IL-17A on stem cell renewal, chemotherapy resistance and tumor spread in colorectal cancer.
While the AJCC/CAP Regression Grading scale for rectal cancer response was based on expert consensus, the clinical relevance of the scoring had not been validated — until a recent Cleveland Clinic study.
From a brand-new, 377,000-square-foot cancer building opening in 2017 to standardizing care, discover how Cleveland Clinic is changing the way it delivers colorectal cancer care.
From intervening in colorectal-related cancer to utilizing a gold mine of outcomes data, discover how the latest bench research at Cleveland Clinic may one day improve outcomes for colorectal cancer patients.